AU2022327397A1 - Anti-vegf a and -vegf c bispecific antibody and use thereof - Google Patents

Anti-vegf a and -vegf c bispecific antibody and use thereof Download PDF

Info

Publication number
AU2022327397A1
AU2022327397A1 AU2022327397A AU2022327397A AU2022327397A1 AU 2022327397 A1 AU2022327397 A1 AU 2022327397A1 AU 2022327397 A AU2022327397 A AU 2022327397A AU 2022327397 A AU2022327397 A AU 2022327397A AU 2022327397 A1 AU2022327397 A1 AU 2022327397A1
Authority
AU
Australia
Prior art keywords
amino acid
acid sequence
seq
antibody
polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2022327397A
Other languages
English (en)
Inventor
Bingliang Chen
Siyi Hu
Yiming Li
Shuaixiang ZHOU
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Innovent Biologics Suzhou Co Ltd
Original Assignee
Innovent Biologics Suzhou Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Innovent Biologics Suzhou Co Ltd filed Critical Innovent Biologics Suzhou Co Ltd
Publication of AU2022327397A1 publication Critical patent/AU2022327397A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2022327397A 2021-08-13 2022-08-11 Anti-vegf a and -vegf c bispecific antibody and use thereof Pending AU2022327397A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN202110932078 2021-08-13
CN202110932078.7 2021-08-13
PCT/CN2022/111717 WO2023016516A1 (zh) 2021-08-13 2022-08-11 抗vegf a和vegf c双特异性抗体及其用途

Publications (1)

Publication Number Publication Date
AU2022327397A1 true AU2022327397A1 (en) 2024-03-14

Family

ID=85200580

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2022327397A Pending AU2022327397A1 (en) 2021-08-13 2022-08-11 Anti-vegf a and -vegf c bispecific antibody and use thereof

Country Status (7)

Country Link
US (1) US20250002570A1 (https=)
EP (1) EP4386004A4 (https=)
JP (1) JP2024529119A (https=)
CN (1) CN118043350A (https=)
AU (1) AU2022327397A1 (https=)
CA (1) CA3229250A1 (https=)
WO (1) WO2023016516A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4663202A1 (en) * 2023-02-10 2025-12-17 Innovent Biologics (Suzhou) Co., Ltd. Pharmaceutical preparation containing anti-vegfa and anti-vegfc bispecific binding protein
WO2025250739A1 (en) * 2024-05-31 2025-12-04 Janssen Biotech, Inc. Chimeric antigen receptor with spacer domains derived from human igg

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6403088B1 (en) * 1995-08-01 2002-06-11 Helsinki University Licensing, Ltd. Antibodies reactive with VEGF-C, a ligand for the Flt4 receptor tyrosine kinase (VEGFR-3)
KR100816621B1 (ko) 1997-04-07 2008-03-24 제넨테크, 인크. 항-ｖｅｇｆ 항체
WO2011071577A1 (en) * 2009-12-11 2011-06-16 Genentech, Inc. Anti-vegf-c antibodies and methods using same
EP2558122A4 (en) * 2010-04-15 2014-03-05 Vegenics Pty Ltd COMBINATION TREATMENT WITH VEGF-C ANTAGONISTS
US20120225081A1 (en) * 2010-09-03 2012-09-06 Boehringer Ingelheim International Gmbh Vegf-binding molecules
US9527925B2 (en) * 2011-04-01 2016-12-27 Boehringer Ingelheim International Gmbh Bispecific binding molecules binding to VEGF and ANG2
JP5987057B2 (ja) * 2011-07-27 2016-09-06 グラクソ グループ リミテッドＧｌａｘｏ Ｇｒｏｕｐ Ｌｉｍｉｔｅｄ Ｆｃドメインと融合した抗ｖｅｇｆ単一可変ドメイン
KR102131370B1 (ko) * 2013-10-18 2020-07-08 삼성전자주식회사 Vegf-c에 특이적으로 결합하는 폴리펩타이드 및 그의 용도
WO2016172485A2 (en) * 2015-04-24 2016-10-27 Genentech, Inc. Multispecific antigen-binding proteins
CN108640994A (zh) * 2018-06-28 2018-10-12 浙江众意生物科技有限公司 一种vegf-c单克隆抗体及试剂盒
CN112961250B (zh) * 2021-03-01 2023-06-06 长春金赛药业有限责任公司 抗体融合蛋白及其应用

Also Published As

Publication number Publication date
WO2023016516A1 (zh) 2023-02-16
JP2024529119A (ja) 2024-08-01
EP4386004A4 (en) 2025-08-13
CN118043350A (zh) 2024-05-14
EP4386004A1 (en) 2024-06-19
US20250002570A1 (en) 2025-01-02
CA3229250A1 (en) 2023-02-16

Similar Documents

Publication Publication Date Title
JP7177543B2 (ja) 抗ｐｄ－ｌ１／抗ｌａｇ３二重特異性抗体およびその使用
KR20140019375A (ko) 인간 조직 인자 항체 및 이의 용도
EP4349861A1 (en) Bispecific binding molecule binding vegf and ang2 and use thereof
KR20210142638A (ko) Cd3 항원 결합 단편 및 이의 응용
AU2021352532B2 (en) Anti-claudin18.2 and cd3 bispecific antibody and use thereof
US11008387B2 (en) Antibody inhibiting binding of VEGF to NRP1
AU2021390121A1 (en) Anti-human b7-h3 antibody and application thereof
KR20240004860A (ko) 디엘엘3에 대한 결합 분자 및 이의 용도
JP2019531762A (ja) Ｖｅｇｆに対する合成の抗体およびそれらの使用
CN114685655A (zh) Pd-1结合分子及其应用
KR20240109605A (ko) 항-인간 cd3 항체 및 이의 응용
TW202246341A (zh) 針對NKp46的抗體及其應用
US20250002570A1 (en) Anti-vegf a and vegf c bispecific antibodies and use thereof
EP4628512A1 (en) Trispecific fusion protein and use thereof
CN119698434A (zh) 抗gprc5d纳米抗体及其应用
US20230265181A1 (en) Single variable domain and antigen binding molecule binding bcma
AU2022217845A1 (en) Anti-tnfr2 antibody and use thereof
EP4628097A1 (en) Preparation containing bispecific binding molecule binding to vegf and ang2 and use thereof
WO2024012434A1 (en) Antibody, antigen-binding fragment thereof, and pharmaceutical use thereof
US20250043016A1 (en) Tnfr2 binding molecule and use thereof
WO2024114244A1 (zh) 抗cd100抗体及其用途
CN118556082A (zh) p95HER2抗体及其应用
JP2024532540A (ja) 二機能性融合タンパク質およびその用途
CN119409815B (zh) 抗人补体c5 vhh抗体及其应用
CN117043192B (zh) 针对IL-13Rα2的抗体及其应用